What is the most recent earnings date for GYRE stock?
GYRE THERAPEUTICS INC (GYRE) last reported earnings on 3/12/2026.
GYRE THERAPEUTICS INC (GYRE) Earnings History & Surprises
NASDAQ:GYRE • US4037831033
Current stock price
7.04 USD
-0.14 (-1.95%)
At close:
7.04 USD
0 (0%)
After Hours:
GYRE Earnings overview
Past quarterly earnings results for GYRE THERAPEUTICS INC (GYRE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.01
- Revenue Estimate
- 36.465M
Last Reported
Most Recent- Release Date
- Mar 12, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.05
- EPS Surprise
- -13.50%
- Revenue Surprise
- 2.90%
Beat Rate
Last 8 Quarters 0%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.05 | 0.06 | -13.50% | 4,447.83% | 37.195M | 36.145M | 2.90% | 33.45% |
| Q3 2025 | 0.08 | 0.03 | 194.08% | - | 30.564M | 33.589M | -9.01% | 19.92% |
| Q2 2025 | 0.02 | 0.03 | -34.64% | - | 26.771M | 31.416M | -14.79% | 6.13% |
| Q1 2025 | 0.03 | 0.03 | -1.96% | - | 22.058M | 28.968M | -23.85% | -18.82% |
| Q4 2024 | 0.00 | 0.04 | -102.82% | 99.81% | 27.872M | 23.97M | 16.28% | -75.43% |
| Q3 2024 | - | - | 25.488M | - | - | |||
| Q2 2024 | - | - | 25.225M | - | - | |||
| Q1 2024 | - | - | 27.172M | - | - | |||
| Q4 2023 | -0.61 | - | 61.90% | 113.45M | - | - | ||
| Q3 2023 | -1.05 | -0.77 | -37.25% | 56.25% | - | - | ||
| Q2 2023 | -1.05 | -1.07 | 1.96% | 61.11% | - | - | ||
| Q1 2023 | 0.15 | -1.07 | 114.01% | 102.17% | - | -100.00% | ||
| Q4 2022 | -1.61 | - | 83.27% | - | -100.00% | |||
| Q3 2022 | -2.40 | -1.53 | -56.86% | 80.00% | - | -100.00% | ||
| Q2 2022 | -2.70 | -3.75 | 27.97% | 71.88% | - | -100.00% | ||
| Q1 2022 | -6.90 | -6.78 | -1.73% | 41.77% | 790K | - | -46.26% | |
| Q4 2021 | -9.60 | -8.99 | -6.80% | 25.58% | 2.44M | 170.003K | 1,335.27% | 20.20% |
| Q3 2021 | -12.00 | -10.10 | -18.84% | -9.59% | 2.3M | 688.5K | 234.06% | 158.43% |
| Q2 2021 | -9.60 | -10.63 | 9.72% | 33.33% | 1.13M | 339.997K | 232.36% | -31.93% |
| Q1 2021 | -11.85 | -8.84 | -34.11% | -182.14% | 1.47M | 816K | 80.15% | -91.02% |
| Q4 2020 | -12.90 | -13.20 | 2.24% | - | 2.03M | 51K | 3,880.39% | - |
| Q3 2020 | -10.95 | -12.34 | 11.28% | - | 890K | 1.071M | -16.90% | - |
| Q2 2020 | -14.40 | -13.20 | -9.12% | - | 1.66M | 306K | 442.48% | - |
| Q1 2020 | -4.20 | -5.58 | 24.79% | - | 16.37M | 8.109M | 101.87% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
1
Average EPS beat (4)
35.99%
Max EPS beat (4)
194.08%
Min EPS beat (4)
-34.64%
Revenue beat statistics
Revenue beat (4)
1
Average Revenue beat (4)
-11.19%
Max Revenue beat (4)
2.90%
Min Revenue beat (4)
-23.85%
Analysis
In the last 4 quarters, GYRE has beaten EPS estimates in 1 out of 4 releases
GYRE has beaten revenue estimates in 1 out of the last 4 releases
In the last 4 quarters, GYRE has beaten the EPS estimates by 36.0% on average.
In the last 4 quarters, GYRE reported -11.2% below the revenue estimates on average.
Related analysis
GYRE THERAPEUTICS INC / GYRE Earnings FAQ
Can you provide information on whether GYRE THERAPEUTICS INC beat earnings estimates in the last quarter?
GYRE THERAPEUTICS INC (GYRE) missed EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often GYRE THERAPEUTICS INC beats earnings estimates?
In the last 4 quarters, GYRE THERAPEUTICS INC (GYRE) has beaten EPS estimates in 1 out of 4 releases.